atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods.
Read full article here.
The UK's national research agency is backing a plan to speed up dementia testing with up to £80 million ($105.48 million) in funding, to improve diagnosis rates and cut waiting times that can exceed a year.
Read full article at Medscape…
Attendees
Sponsors and Exhibitors
Contact us